Josep Quer Sivila I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies. Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Josep Quer Sivila LinkedIn Twitter Orcid Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies.
Senior Researcher at Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus from 2021 (indefinite contract). Associate Professor at the Biochemistry and Molecular Department of the UAB from 2021 to present (3933001435 Y0LOU0146). Accredited researcher at CIBERehd (2010-prest). Accredited as Professor (Catedrático) from AQU (Generalitat de Catalunya) from 2023. Academic background: Bachelor in Biology from UB (1981-86). PhD in Biology from UAB (1994) with extraordinary award. Postdoctoral stay in the University of California at San Diego USA (1994-96). Member of Ciberehd since 2007-act. Associate Professor (AP) of Immunology, UB (1988-89); AP Medicine, UAB (2003-18); AP of Biochemistry and Molecular Biology, UAB (2021-pres.). General Coordinator Master in "Translational Biomedical Research" VHIR-UAB (2020-pres.). Professor and coordinator of Module 1 Master in "Translational Biomedical Research" VHIR-UAB since 2014-pres. Scientific and professional activities: Projects: Since 2016, he has led 10 overlapping competitive financed projects, serving as the Principal Investigator (PI) in eight national projects and as the co-IP of the local-node in two European Union projects. Thesis: 6 PhD thesis directed, and 3 under development. Papers and reviews: 154 papers; 8 book chapters & 1 book published in 2023. Meetings participation: 220, 66 of them as invited speaker. Other merits: Member Coordinator Committee “Strategic Plan for Tackling hepatitis C (PEAHC) Spanish Ministry of Health; Treasurer Spanish Society of Virology (SEV) (2009-pres.); Member of scientific societies (ESV;AEEH;SCB) and of Alliance for the Elimination of Hepatitis in Spain (AEHVE). Organizing Committee of International Symposium Fundación Ramón Areces (2013); and SEV National Meetings (2013-2015-2017-2019-2022). Impacts printed, digital, radio and TV. NGS-2010: 32 impacts; HCV-2015: 69 impacts; SARS-CoV-2 – 2020-23: 90 impacts. Awards: Ciudad de Barcelona (1996); Best ideas Diario Medico (2015); Premi Ciència i Tecnologia Diari Regió7-Prensa Ibérica (2020). Metrics: h-index:41 (scholar), 35 (WoS), 37 (Scopus); i10-index: 116; Citations (WoS): 8371; Views: >40000. ORCID: 0000-0003-0014-084X // WOS ResearcherID A-6741-2012 // SCOPUS ID: 7004592398 Social media: Linkedin: Josep Quer Twitter (X): @JosepQuerSivila / @VirusLabQ (Virus Lab by Dr. Josep Quer) / @HepatitisSEV
Líneas de investigación Hepatitis virals - biologia molecular Subtipat i resistències del virus de la hepatitis C Quasispècies del virus de la hepatitis E Exosomes hepàtics en malalties hepàtiques i tumors hepàtics Identificació, caracterització i variabilitat d’agents virals per seqüenciació massiva, Next Generation Sequencing (NGS) Serveis o tecnologies rellevants Seqüenciació Sanger i massiva (NGS) Extracció i amplificació àcids nucleics Filogènia molecular disseny primers Tècniques de Biologia Molecular Gradients per aïllament i estudi d'exosomes en plasma i femta Citometria de Flux Resposta immune cel·lular Cultius Clonació, expressió de proteïnes recombinants en cultius cel·lulars Bioinformàtica IP: Juan Ignacio Esteban Mur, Josep Quer Sivila Proyectos Application of bioinformatic tools in the diagnosis of infectious diseases through metagenomics and deep-sequencing IP: Josep Quer Sivila Colaboradores: Miriam Izquierdo Sans Entidad financiadora: Fundació "La Caixa" Financiación: 117900 Referencia: 132074 Duración: 01/09/2023 - 31/08/2026 Beca VHIR PhD IP: Josep Quer Sivila Colaboradores: Sira Rodrigo Bosch, Laia Perez Lasarte, Carolina Campos Martinez Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 69188.74 Referencia: VPHD/CAROLINA_C Duración: 01/04/2023 - 31/03/2026 Estudio de quasispecies por metagenómica en neuropatías asociadas a virus por secuenciación masiva de nueva generación. IP: Josep Quer Sivila Colaboradores: Sergi Colomer Castell, Lluís Viladomiu Catà, Damir Garcia Cehic, Maria Piñana Moro, Pablo Gabriel Medina, Arnau Llauradó Gayete, Carolina Campos Martinez, Alejandra Gonzalez Sánchez Entidad financiadora: Instituto de Salud Carlos III Financiación: 292820 Referencia: PI22/00258 Duración: 01/01/2023 - 31/12/2025 FPU 2021 IP: Josep Quer Sivila Colaboradores: Sergi Colomer Castell Entidad financiadora: Ministerio de Universidades Financiación: 73389.26 Referencia: FPU21/04150 Duración: 16/12/2022 - 15/05/2025 Paginación Página actual 1 Página 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »
